carvedilol has been researched along with Ascites in 14 studies
Ascites: Accumulation or retention of free fluid within the peritoneal cavity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 9.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| " Baseline ascites severity and UK end-stage liver disease (UKELD) score between carvedilol (n=132) and non-carvedilol (n=132) treated patient groups were comparable." | 7.85 | Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. ( Hayes, PC; Lockman, KA; Mallawaarachchi, N; Plevris, JN; Robertson, M; Sinha, R, 2017) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 6.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| " First-line therapies include carvedilol or propranolol to prevent variceal bleeding, lactulose for hepatic encephalopathy, combination aldosterone antagonists and loop diuretics for ascites, and terlipressin for hepatorenal syndrome." | 5.41 | Diagnosis and Management of Cirrhosis and Its Complications: A Review. ( Parikh, ND; Tapper, EB, 2023) |
| "In recent years, concerns have been raised on the potential adverse effects of nonselective beta-blockers, and particularly carvedilol, on renal perfusion and survival in decompensated cirrhosis with ascites." | 5.41 | Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. ( Aggelis, N; Baltayiannis, G; Christaki, M; Christodoulou, D; Despotis, G; Fillipas-Ntekouan, S; Fotopoulos, A; Kalambokis, GN; Koustousi, C; Lakkas, L; Michalis, LK; Milionis, H; Pappas, K; Sergianiti, F; Tsiakas, I; Tsiouris, S; Xourgia, X, 2021) |
| " Baseline ascites severity and UK end-stage liver disease (UKELD) score between carvedilol (n=132) and non-carvedilol (n=132) treated patient groups were comparable." | 3.85 | Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. ( Hayes, PC; Lockman, KA; Mallawaarachchi, N; Plevris, JN; Robertson, M; Sinha, R, 2017) |
| "Portal hypertension is the primary driver of decompensation, including the development of ascites, hepatic encephalopathy and variceal haemorrhage." | 3.01 | Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis. ( Gillespie, SL; Hanrahan, TP; Hayes, PC; Majumdar, A; Rockey, DC, 2023) |
| "Carvedilol is a non-selective beta-blocker (NSBB) acting on hyperdynamic circulation/splanchnic vasodilation and on intrahepatic resistance." | 3.01 | Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension. ( La Mura, V; Reiberger, T; Turco, L; Vitale, G, 2023) |
| "Propranolol has been used as prophylaxis for variceal bleeding in patients with cirrhosis." | 2.82 | A Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy of Carvedilol vs. Propranolol to Reduce Portal Pressure in Patients With Liver Cirrhosis. ( Baik, SK; Jang, JY; Jeong, SW; Kim, DJ; Kim, MY; Kim, SG; Kim, TY; Kim, YS; Lee, B; Seo, YS; Sohn, JH; Suk, KT; Um, SH, 2016) |
| "Carvedilol is a potent noncardioselective beta-blocker, with weak vasodilating properties because of alpha 1 blockade." | 2.46 | The role of carvedilol in the management of portal hypertension. ( Hayes, PC; Tripathi, D, 2010) |
| "Treatment with carvedilol had an inverse relation with SDANN." | 1.91 | Heart rate variability is associated with disease severity and portal hypertension in cirrhosis. ( Amodio, E; Basso, MG; Cabibbo, G; Calvaruso, V; Casuccio, A; Craxì, A; Daidone, M; Di Raimondo, D; Licata, M; Miceli, G; Pennisi, G; Petta, S; Pinto, A; Pintus, C; Simone, F; Tuttolomondo, A; Velardo, M, 2023) |
| "Ascites is associated with a high risk of death." | 1.72 | Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. ( Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (50.00) | 24.3611 |
| 2020's | 7 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tapper, EB | 2 |
| Zhao, Z | 1 |
| Mazumder, N | 1 |
| Parikh, ND | 2 |
| Villanueva, C | 2 |
| Torres, F | 2 |
| Sarin, SK | 1 |
| Shah, HA | 1 |
| Tripathi, D | 2 |
| Brujats, A | 1 |
| Rodrigues, SG | 1 |
| Bhardwaj, A | 1 |
| Azam, Z | 1 |
| Hayes, PC | 5 |
| Jindal, A | 1 |
| Abid, S | 1 |
| Alvarado, E | 2 |
| Bosch, J | 2 |
| Gillespie, SL | 1 |
| Hanrahan, TP | 1 |
| Rockey, DC | 1 |
| Majumdar, A | 1 |
| Miceli, G | 1 |
| Calvaruso, V | 1 |
| Casuccio, A | 1 |
| Pennisi, G | 1 |
| Licata, M | 1 |
| Pintus, C | 1 |
| Basso, MG | 1 |
| Velardo, M | 1 |
| Daidone, M | 1 |
| Amodio, E | 1 |
| Petta, S | 1 |
| Simone, F | 1 |
| Cabibbo, G | 1 |
| Di Raimondo, D | 1 |
| Craxì, A | 1 |
| Pinto, A | 1 |
| Tuttolomondo, A | 1 |
| Turco, L | 1 |
| Reiberger, T | 2 |
| Vitale, G | 1 |
| La Mura, V | 1 |
| Kalambokis, GN | 1 |
| Christaki, M | 1 |
| Tsiakas, I | 1 |
| Despotis, G | 1 |
| Fillipas-Ntekouan, S | 1 |
| Fotopoulos, A | 1 |
| Tsiouris, S | 1 |
| Xourgia, X | 1 |
| Lakkas, L | 1 |
| Pappas, K | 1 |
| Michalis, LK | 1 |
| Sergianiti, F | 1 |
| Baltayiannis, G | 1 |
| Christodoulou, D | 1 |
| Koustousi, C | 1 |
| Aggelis, N | 1 |
| Milionis, H | 1 |
| Sinha, R | 2 |
| Lockman, KA | 2 |
| Plevris, JN | 2 |
| Brito-Azevedo, A | 1 |
| Albillos, A | 1 |
| Genescà, J | 1 |
| Garcia-Pagan, JC | 1 |
| Calleja, JL | 1 |
| Aracil, C | 1 |
| Bañares, R | 1 |
| Morillas, RM | 1 |
| Poca, M | 1 |
| Peñas, B | 1 |
| Augustin, S | 1 |
| Abraldes, JG | 1 |
| Kim, SG | 1 |
| Kim, TY | 1 |
| Sohn, JH | 1 |
| Um, SH | 1 |
| Seo, YS | 1 |
| Baik, SK | 1 |
| Kim, MY | 1 |
| Jang, JY | 1 |
| Jeong, SW | 1 |
| Lee, B | 1 |
| Kim, YS | 1 |
| Suk, KT | 1 |
| Kim, DJ | 1 |
| Mandorfer, M | 1 |
| Mallawaarachchi, N | 1 |
| Robertson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Novel Algorithm to Stratify Clinical Decompensation Risk in Patients With Compensated Advanced Chronic Liver Disease (CHESS2108)[NCT05100485] | 1,000 participants (Actual) | Observational | 2022-01-01 | Completed | |||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension[NCT01059396] | Phase 4 | 201 participants (Actual) | Interventional | 2010-01-28 | Completed | ||
| CHESS-SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease: an International Multicenter Study (CHESS2102)[NCT04975477] | 1,000 participants (Anticipated) | Observational | 2021-07-16 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for carvedilol and Ascites
| Article | Year |
|---|---|
Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Humans; Hypertensi | 2022 |
Review article: controversies surrounding the use of carvedilol and other beta blockers in the management of portal hypertension and cirrhosis.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.
Topics: Adrenergic beta-Antagonists; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal H | 2023 |
Diagnosis and Management of Cirrhosis and Its Complications: A Review.
Topics: Adult; Ascites; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hepatic Enc | 2023 |
Beta blockers and cirrhosis, 2016.
Topics: Acute Kidney Injury; Adrenergic beta-Antagonists; Ascites; Carbazoles; Carvedilol; Esophageal and Ga | 2017 |
The role of carvedilol in the management of portal hypertension.
Topics: Antihypertensive Agents; Ascites; Benzopyrans; Carbazoles; Carvedilol; Drug Therapy, Combination; Et | 2010 |
3 trials available for carvedilol and Ascites
5 other studies available for carvedilol and Ascites
| Article | Year |
|---|---|
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Huma | 2022 |
Heart rate variability is associated with disease severity and portal hypertension in cirrhosis.
Topics: Ascites; Carvedilol; Cross-Sectional Studies; Esophageal and Gastric Varices; Heart Rate; Humans; Hy | 2023 |
Reply to: "Carvedilol and survival in cirrhosis with ascites: A cognitive bias?"
Topics: Ascites; Carvedilol; Cognition; Humans; Liver Cirrhosis; Propanolamines | 2017 |
Carvedilol and survival in cirrhosis with ascites: A cognitive bias?
Topics: Ascites; Carvedilol; Cognition; Humans; Liver Cirrhosis; Propanolamines | 2017 |
Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites.
Topics: Adrenergic beta-Antagonists; Aged; Ascites; Carbazoles; Carvedilol; Cause of Death; Female; Humans; | 2017 |